What makes it a better choice: Comprehensive coverage for foundational daily nutrient support Women-focused formulation instead of a generic multivitamin approach Twice-daily dosing , which can support better absorption and gentler tolerance for some women Bioavailable nutrients , which matter when digestion and intake are already compromised Support for energy, metabolism, hair, skin, immune health, and overall resilience For women on GLP-1, that combination matters
Who May Be Prescribed Both Treatments in the UK Retatrutide cannot currently be prescribed on the NHS as it is unlicensed
Consider tirzepatide (Zepbound/Mounjaro) if: You want a proven, FDA-approved medication available today You prefer a drug with years of real-world safety data You have insurance coverage for weight management medications You have type 2 diabetes (Mounjaro is indicated for T2D) You are sensitive to GI side effects (lower nausea rate: 31% vs 43%) You want the option of pre-filled pens for easier injection Consider waiting for retatrutide if: You have plateaued on tirzepatide or semaglutide and want the next-generation option You have MASLD or fatty liver disease (glucagon component reduces liver fat by 82%) Maximum possible weight loss is your primary goal You are eligible for and enrolled in a clinical trial You are comfortable waiting until 2027-2028 for availability On switching from tirzepatide to retatrutide: Once retatrutide is approved, switching will likely be straightforward since both are Lilly products
Your lifestyle: Are you willing to inject yourself once a week, or would you prefer a daily pill
